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Preventive, Paris, FranceAbstractOver two million Muslim pilgrims assemble annually in Mecca and Medina, Saudi Arabia, to complete the Hajj. The large number of people in a
crowded environment increases the potential for pneumococcal carriage ampliﬁcation. We evaluated pneumococcal carriage prevalence with
four cross-sectional studies conducted at beginning-Hajj (Mecca) and end-Hajj (Mina) during 2011 and 2012. A questionnaire was
administered and a nasopharyngeal swab was collected. The swab was tested for pneumococcus, serotype and antibiotic resistance. A
total of 3203 subjects (1590 at beginning-Hajj and 1613 at end-Hajj) originating from 18 countries in Africa or Asia were enrolled. The
overall pneumococcal carriage prevalence was 6.0%. There was an increase in carriage between beginning-Hajj and end-Hajj cohorts for:
overall carriage (4.4% versus 7.5%, prevalence ratio (PR) 1.7, 95% CI 1.3–2.3), and carriage of 23-valent pneumococcal polysaccharide
vaccine serotypes (2.3% versus 4.1%, PR 1.8, 95% CI 1.2–2.7), 13-valent pneumococcal conjugate vaccine (PCV) serotypes (1.1% versus
3.6%, PR 3.2, 95% CI 1.9–5.6), 10-valent PCV serotypes (0.6% versus 1.6%, PR 2.6, 95% CI 1.2–5.3), antibiotic non-susceptible isolates
(2.5% versus 6.1%, PR 2.5, 95% CI 1.7–3.6) and multiple non-susceptible isolates (0.6% versus 2.2%, PR 3.8, 95% CI 1.8–7.9). Fifty-two
different serotypes were identiﬁed, most commonly serotypes 3 (17%), 19F (5%) and 34 (5%). These results suggest that the Hajj may
increase pneumococcal carriage—particularly conjugate vaccine serotypes and antibiotic non-susceptible strains, although the exact
mechanism remains unknown. The Hajj may therefore provide a mechanism for the global distribution of pneumococci.
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E-mail: zmemish@yahoo.comIntroductionStreptococcus pneumoniae causes a broad spectrum of illnesses
ranging from mild upper respiratory tract infection to severe
invasive disease. The World Health Organization has estimated
that 1.6 million deaths are caused by pneumococci annually [1].Clinical Microbiology and Infection © 2014 European Society of CPneumococcal infection, or carriage, is a precursor to pneu-
mococcal disease and carriage prevalence may vary greatly
across settings from <5% to >50% [2]. Pneumococcal vaccines
are widely available and the US CDC recommends that US
adults receive vaccination if they are aged 65 years or aged
19–64 years and at high risk of pneumococcal disease [3].
While 23-valent pneumococcal polysaccharide vaccine (PPV23)
does not impact carriage [4], newer 7-, 10- and 13-valent
pneumococcal conjugate vaccines (PCV) do; this effect is of
such a magnitude that indirect vaccine effects through reduc-
tion of carriage and transmission might outweigh direct pro-
tection [5].Clin Microbiol Infect 2015; 21: 77.e11–77.e18
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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than two million Muslim pilgrims from around 184 countries
during the Hajj pilgrimage [6]. The presence of such a large
number of pilgrims from across the globe in close contact
creates conditions where the potential for transmission of in-
fectious organisms is high [7,8], including those related to se-
vere diseases such as pneumonia. Pneumonia is one of the
leading causes of hospitalization and intensive care unit care
among pilgrims in Saudi hospitals during Hajj [9,10]. During the
1986 Hajj season, pneumonia was the second most common
cause of hospitalization with the highest case fatality ratio
among those aged over 50 years [11].
Although limited data are available on the microbiological
causes of pneumonia during Hajj, S. pneumoniae appears to be a
common pathogen isolated from patients with pneumonia and
respiratory tract infections [10,12,13]. Among 395 sputum
samples collected from Hajjis with respiratory tract infections
in 1991 and 1992, S. pneumoniae was detected in 4.8% and
12.3% respectively [12], while sputum samples from 64 patients
with pneumonia admitted into two tertiary hospitals in Mecca
during the 1994 Hajj yielded S. pneumoniae in 9.4% of cases
[13]. Invasive pneumococcal disease has also been reported in
Hajj pilgrims with six of nine cases of acute bacterial meningitis
caused by S. pneumoniae in 2003 [9].
While substantial work has been performed on transmission
during the Hajj of Neisseria meningitidis group A [14–16],
inﬂuenza [17–19] and respiratory diseases as a whole [20–22],
limited data are available for pneumococcal disease. In addition,
although the dominant invasive pneumococcal serotypes in KSA
among adults and children are 4, 3, 19F, 9V, 6A, 19A, 14 and
23F (accounting for 75% of all serotypes) [23], the current
serotype distribution among Hajj pilgrims is unknown.
If the Hajj increases pneumococcal carriage, several potential
consequences may follow. First, pilgrims may experience more
acute infections due to contact with more invasive clones.
Second, transmission of more invasive serotypes or antibiotic-
resistant clones may lead to more disease or disease that is
more difﬁcult to treat in pilgrims’ countries of origin after the
Hajj. Finally, the mix of pneumococcal serotypes at the Hajj may
facilitate serotype replacement in countries that have imple-
mented routine infant vaccination with PCV. The ﬁrst step in
determining the plausibility of these outcomes is to document
whether pneumococcal carriage prevalence increases during
the Hajj and if so, with which serotypes and clones.
A recent small cohort survey of 169 French pilgrims per-
forming the 2012 Hajj demonstrated the acquisition of
S. pneumoniae nasal carriage among returning pilgrims [24]. The
authors of the study called for large-scale studies to conﬁrm the
result of their small-scale preliminary investigation, to detect
speciﬁc serotypes and to better understand the epidemiology ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectS. pneumoniae carriage during mass gathering events. We aimed
to perform such a study by evaluating pneumococcal naso-
pharyngeal carriage prevalence among a large cohort of pilgrims
at the beginning and end of Hajj during two Hajj seasons. We
also determined the serotype, genotype and antimicrobial sus-
ceptibility proﬁles of identiﬁed S. pneumoniae isolates.
Materials and methodsStudy design
The Hajj progresses through a series of stages, commencing in
Mecca and ending in Mina, KSA. We conducted four prospective,
cross-sectional, carriage studies with cohorts tested in Mecca
(beginning-Hajj) and Mina (end-Hajj) during each of the 2011 and
2012 Hajj seasons. This design was selected because of the difﬁ-
culty in following individual subjects throughout the Hajj period.
Study population
During the 2011 and 2012 Hajj seasons, we screened 3203
pilgrims (1590 at the beginning of the Hajj and 1613 at the end
of the Hajj). The study population consisted of a convenience
sample of pilgrims 18 years of age and older originating from 18
countries in Africa or Asia (see Supporting information,
Table S1). Among represented countries, only Ethiopia had
introduced a PCV into routine infant immunization pro-
grammes and coverage was estimated at 12% (website: http://
apps.who.int/immunization_monitoring/globalsummary, last
accessed 5 June 2014). A study population of 3200 was
designed to provide 80% power to detect a prevalence ratio of
1.4 at the 95% conﬁdence level in the end-Hajj compared to the
beginning-Hajj cohorts, given a beginning of Hajj pneumococcal
carriage prevalence of 2%.
A standardized data collection form was used to obtain in-
formation from the beginning-Hajj cohort regarding the par-
ticipants’ age, gender, country of origin, formal education,
smoking habits, medical conditions and vaccination history. A
similar form was used for the end-Hajj cohort except that it
also included data related to the Hajj such as clinical illness
during the event, medication use and housing conditions, from
the end-Hajj cohort.
The exclusion criteria were pilgrims under 18 years of age
and those who refused to participate and give consent.
Sample collection and processing
A nasopharyngeal sample was collected from all participants by
trained physicians using a dacron polyester-tipped nasopha-
ryngeal swab. For the beginning-Hajj cohort, the nasopharyn-
geal swab was collected within 2 days of arrival in Mecca, while
for the end-Hajj cohort collection was at anytime after arrival inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e11–77.e18
CMI Memish et al. Hajj pneumococcal carriage ampliﬁcation 77.e13Mina. Following collection, swabs were inserted into skim milk-
tryptone-glucose-glycerin [25], placed on wet ice and trans-
ported each half-day (within 4 hours) to the processing
laboratory.
Microbiological identiﬁcation, antimicrobial
susceptibility testing and serological and molecular
typing
Standard microbiological procedures for the identiﬁcation of
pneumococcus were used [25]. Brieﬂy, upon delivery to the
laboratory, swabs were streaked immediately onto Trypticase
soy agar + 5% sheep blood plates containing nalidixic acid and
colistin to inhibit the growth of other organisms. A single pure
colony of pneumococcus was selected and stored at –80 °C for
colony conﬁrmation and further testing by the reference
laboratory.
In Germany, isolates identiﬁed as pneumococcus in Saudi
Arabia were re-plated on 5% sheep blood agar plates and tested
for optochin susceptibility and bile-solubility. In case of doubt,
lytA, sodA and 16S rDNA sequencing were used to unambig-
uously identify S. pneumoniae and rule out related viridians
streptococci like Streptococcus pseudopneumoniae, Streptococcus
mitis and Streptococcus oralis. Finally, serotyping and multilocus
sequence typing (MLST; see below) were used to conﬁrm
S. pneumoniae.
Antibiotic susceptibility testing of the isolates was performed
using the microdilution method based on breakpoints from the
2011 CLSI catalogue (see Supporting information, Table S2).
Multiple non-susceptibility was deﬁned as non-susceptibility to
three or more antibiotics.
Serotyping was performed using the Neufeld’s Quellung
reaction [26] with group and factor sera provided by the
Statens Serum Institute, Copenhagen, Denmark. MLST of iso-
lates was performed as described previously [27]. The allelic
proﬁles were compared with each other and with other isolates
in the pneumococcal MLST database using software available at
www.mlst.net. Clusters of related sequence types (STs) were
grouped into clonal complexes using the program EBURST
(www.mlst.net).
Statistical analysis
We conducted bivariate analyses of the relationship between
pneumococcal carriage and beginning-Hajj versus end-Hajj status
stratiﬁed by gender, age, country of origin, underlying disease
status, cigarette smoking history, formal education and pneu-
mococcal or inﬂuenza vaccination history. During multivariate
analysis, we included variables that were associated with (at the
95% conﬁdence level) overall pneumococcal carriage at the
beginning or end of the Hajj including age and self-reported
previous inﬂuenza or pneumococcal vaccination. MultivariateClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inmodels were created for different categories of pneumococcal
serotypes (10- and 13-valent PCV serotypes (PCV10 and PCV13,
respectively) and PPV23), and antibiotic non-susceptibility; all
potential confounding variables were entered simultaneously. All
analyses were conducted with SPSS version 19.0.
Ethics
The KSA Institutional Review Board approved the study. We
obtained informed consent from all study participants. During
2011, written consent was obtained; during 2012, for practi-
cality and efﬁciency, the study Institutional Review Board
approved the use of verbal consent. All adults that provided
consent were enrolled regardless of gender, age or race. The
study was conducted in accordance with internationally
accepted standards, including the Declaration of Helsinki and
Good Clinical Practices. All data were entered into a password-
protected computer. Identiﬁable information (name and date of
birth) was kept only on computers in Saudi Arabia and will be
deleted once the study database is closed.ResultsA total of 3203 subjects (1590 at beginning of Hajj and 1613 at
end of Hajj, all unique individuals) originating from 18 countries
in Africa or Asia were enrolled in the study. For the beginning-
Hajj cohort, sampling occurred in Mecca on days 0 to 2 after
arrival in KSA (mean 1.2 days, median 1 day; see Supporting
information, Figure S1) and included 619 subjects in 2011 and
971 subjects in 2012. For the end-Hajj cohort, enrolment
occurred in Mina on days 7 to 50 after arrival in KSA (mean 18
days, median 16 days) and included 611 subjects in 2011 and
1002 subjects in 2012. The mean age of participants was 53
years (range 18–101 years) with a male : female ratio of 1.7 : 1
and Africa : Asia ratio of 1 : 1.
The overall pneumococcal carriage prevalence among all
four cohorts was 6.0% (191/3203) including 3.3% for PPV23,
2.3% for PCV13 and 1.1% for PCV10. There was a statistically
signiﬁcant increase in carriage between beginning-Hajj and end-
Hajj cohorts (Table 1) for overall carriage (4.4% versus 7.5%),
carriage of various serotypes (PPV23, 2.3% versus 4.1%; PCV13,
1.1% versus 3.6%; and PCV10, 0.6% versus 1.6%) and antibiotic
non-susceptible isolates (non-susceptible to at least one anti-
biotic, 2.5% versus 6.1%; and multiple non-susceptible isolates,
0.6% versus 2.2%). Overall carriage prevalence and the differ-
ence in pneumococcal carriage between beginning-Hajj and
end-Hajj cohorts varied within some categories, particularly
age, residence in Africa or Asia, and previous receipt of
pneumococcal or inﬂuenza vaccine (see Supporting
information, Table S1).fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e11–77.e18
TABLE 1. Prevalence of any pneumococcal carriage and carriage at end-Hajj compared with beginning-Hajj stratiﬁed by study year
Pneumococcal category Any carriage Beginning-Hajj carriage End-Hajj carriage PR (95% CI) Adjusted ORa (95% CI)
All years (2011 and 2012)
n 3203 1590 1613
All 191 (6.0%) 70 (4.4%) 121 (7.5%) 1.7 (1.3–2.3) 1.9 (1.3–2.6)
PPV23 105 (3.3%) 37 (2.3%) 68 (4.1%) 1.8 (1.2–2.7) 1.9 (1.2–3.0)
PCV13 73 (2.3%) 17 (1.1%) 56 (3.6%) 3.2 (1.9–5.6) 3.3 (1.8–6.1)
PCV10 36 (1.1%) 10 (0.6%) 26 (1.6%) 2.6 (1.2–5.3) 2.3 (1.0–5.3)
Non-susceptible to one or more antibiotics 137 (4.2%) 39 (2.5%) 98 (6.1%) 2.5 (1.7–3.6) 2.5 (1.6–3.8)
Non-susceptible to three or more antibiotics 44 (1.4%) 9 (0.6%) 35 (2.2%) 3.8 (1.8–7.9) 3.2 (1.4–7.5)
Year 2011
n 1230 619 611
All 94 (7.6%) 43 (6.9%) 51 (8.3%) 1.2 (0.81–1.8) 1.2 (0.80–1.9)
PPV23 49 (4.0%) 21 (3.4%) 28 (4.4%) 1.4 (0.78–2.4) 1.3 (0.71–2.4)
PCV13 35 (2.8%) 11 (1.8%) 24 (3.9%) 2.2 (1.1–4.5) 2.3 (1.1–4.9)
PCV10 15 (1.2%) 6 (1.0%) 9 (1.5%) 1.5 (0.54–4.2) 1.4 (0.46–4.1)
Non-susceptible to one or more antibiotics 60 (4.9%) 23 (3.7%) 37 (6.1%) 1.6 (0.98–2.7) 1.5 (0.89–2.7)
Non-susceptible to three or more antibiotics 18 (1.5%) 4 (0.6%) 14 (2.3%) 3.5 (1.2–11) 2.8 (0.89–9.1)
Year 2012
n 1973 971 1002
All 97 (4.9%) 27 (2.8%) 70 (7.0%) 2.5 (1.6–3.9) 2.8 (1.6–4.9)
PPV23 56 (2.8%) 16 (1.6%) 40 (4.0%) 2.4 (1.4–4.3) 2.6 (1.3–5.5)
PCV13 38 (1.9%) 6 (0.6%) 32 (3.2%) 5.2 (2.2–12) 3.7 (1.3–10)
PCV10 21 (1.1%) 4 (0.4%) 17 (1.7%) 4.1 (1.4–12) 3.8 (0.93–15)
Non-susceptible to one or more antibiotics 77 (3.9%) 16 (1.6%) 61 (6.1%) 3.7 (2.1–6.4) 3.9 (2.0–7.8)
Non-susceptible to three or more antibiotics 26 (1.3%) 5 (0.5%) 21 (2.1%) 4.1 (1.5–11) 3.2 (0.95–11)
Abbreviations: OR, odds ratio; PCV, pneumococcal conjugate vaccine; PPV, pneumococcal polysaccharide vaccine; PR, prevalence ratio.
Note: PPV23, 23-valent pneumococcal polysaccharide vaccine serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F); PCV13,
13-valent pneumococcal conjugate vaccine serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F); PCV10, ten-valent pneumococcal conjugate vaccine serotypes (1, 4, 5,
6B, 7F, 9V, 14, 18C, 19F and 23F).
aOdds ratio adjusted for age, gender, residence in Africa or Asia, and previous receipt of pneumococcal or inﬂuenza vaccine.
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difference in pneumococcal carriage in relation to the date of
sampling. Subjects tested at 10 days or less had a pneumococcal
carriage prevalence of 7.8% (38/490) compared with 8.2% (50/
607) among those tested at 11–20 days and 6.4% (33/516)
among those tested at 20+ days. For the year 2011, the increase
in pneumococcal carriage prevalence between beginning-Hajj
and end-Hajj cohorts was not statistically signiﬁcant except for
the carriage of the PCV13 serotypes. In contrast, for the year
2012, the increase in carriage prevalence was statistically signif-
icant for all categories except for carriage of PCV10 serotypes
and multiple non-susceptible isolates (Table 1).
Risk factors for carriage of any pneumococci and of antibiotic
non-susceptible pneumococci are summarized in Table 2. Old
age was a risk factor for pneumococcal carriage in multivariate
analysis for the beginning-Hajj cohort but only in bivariate
analysis for the end-Hajj cohort. Other evaluated factors were
not associated with carriage in either analysis and for both co-
horts. There were no risk factors associated with antibiotic non-
susceptible pneumococcal carriage including self-reported anti-
biotic use during the Hajj. The goodness-of-ﬁt for all models was
poor, an expected outcome given the lack of association be-
tween the outcomes and most independent variables.
Overall, 52 different serotypes were identiﬁed (Fig. 1)
including most commonly serotypes 3 (33 isolates, 17%), 19F
(10 isolates, 5%) and 34 (10 isolates, 5%); all other serotypes
contributed fewer than ten isolates each. For two isolates, se-
rotypes could not be determined. Serotypes 3 and 19F wereClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectmore common among end-Hajj isolates, whereas the opposite
was true of serotype 34. Multiple non-susceptible pneumococci
were commonly found among serotypes 3, 6B, 19F, and 35A
(see Supporting information, Figure S2). Serotypes associated
with a higher ratio of invasive disease to carriage were found in
nine isolates (three at the beginning of the Hajj and six at the
end). These were serotypes 4 (ﬁve isolates), 7F (two isolates),
14 (one isolate) and 18C (one isolate).
PCV13 serotypes constituted 38% of all pneumococci, 40%
of antibiotic non-susceptible pneumococci and 66% of multiple
non-susceptible pneumococci. Similar ﬁgures for PCV10 were
19%, 21% and 32% and for PPV23 were 54%, 53% and 67%,
respectively.
For 188 of the 191 pneumococcal isolates MLST was per-
formed. A total of 139 different STs were found, of which 91
had not been reported previously to the MLST database
(spneumoniae.mlst.net). Among 68 beginning-Hajj isolates, 59
different STs were found, and 83 different STs were found
among 120 end-Hajj isolates. Stratiﬁed by year, during 2011
there were 38 different STs among 43 beginning-Hajj, and 45
different STs among 52 end-Hajj isolates; during 2012, 23
different STs were found among 25 isolates pre-Hajj, and 42
different STs among 68 post-Hajj isolates. Stratiﬁed by conti-
nent, among African pilgrims no STs were found both
beginning-Hajj and end-Hajj; among Asian pilgrims, a serotype 3,
ST 180 and a serotype 20, ST 5392 isolate were found both
beginning-Hajj and end-Hajj in 2011 and during 2012, a serotype
3, ST 458 isolate was found beginning-Hajj and end-Hajj.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e11–77.e18
TABLE 2. Risk factors for carriage of any and of antibiotic non-susceptible pneumococci at the beginning and end of the Hajj
Risk group Any pneumococcal carriage
Antibiotic non-susceptible
pneumococcal carriage
Cohorta
Bivariate
PR (95% CI)
Multivariateb
OR (95% CI)
Bivariate
PR (95% CI)
Multivariateb
OR (95% CI)
Beginning Hajj
Female (n = 662/1568) 0.76 (0.47–1.2) 0.81 (0.46–1.4) 1.0 (0.51–1.8) 0.96 (0.46–2.0)
Primary or lower formal education (n = 850/1518) 1.2 (0.73–1.9) 1.2 (0.67–2.1) 1.6 (0.83–3.2) 1.6 (0.75–3.4)
Age 50+ years (n = 1006/1587) 0.65 (0.41–1.0) 0.66 (0.38–1.1) 0.83 (0.44–1.6) 0.81 (0.39–1.7)
Resident in Africa (n = 804/1590) 1.2 (0.78–2.0) 1.0 (0.54–1.8) 0.76 (0.40–1.4) 0.61 (0.28–1.3)
Current tobacco cigarette smoking (n = 205/1568) 1.0 (0.50–2.0) 1.7 (0.74–3.8) 1.5 (0.65–3.3) 2.4 (0.89–6.3)
Previous inﬂuenza or pneumococcal vaccination (n = 676/1475)c 0.40 (0.23–0.69) 0.44 (0.22–0.88) 0.50 (0.25–1.0) 0.44 (0.19–1.0)
Chronic respiratory disease (n = 90/1590) 1.0 (0.38–2.7) 1.5 (0.49–4.8) 0.44 (0.061–3.2) 0.33 (0.04–2.7)
End Hajj cohort
Female (n = 424/1559) 1.1 (0.71–1.5) 0.89 (0.51–1.6) 1.1 (0.73–1.7) 1.1 (0.57–2.0)
Primary or lower formal education (n = 759/1471) 1.3 (0.88–1.8) 1.1 (0.68–1.9) 1.2 (0.80–1.8) 1.0 (0.56–1.8)
Age 50 years (n = 961/1604) 1.6 (1.1–2.4) 1.6 (0.92–2.7) 1.5 (0.98–2.3) 1.6 (0.86–2.9)
Resident in Africa (n = 805/1613) 1.1 (0.77–1.5) 1.2 (0.68–2.1) 1.2 (0.80–1.7) 1.3 (0.68–2.5)
Current tobacco cigarette smoking (n = 344/1491) 0.90 (0.58–1.4) 0.96 (0.52–1.8) 0.96 (0.59–1.6) 1.2 (0.62–2.4)
Previous inﬂuenza or pneumococcal vaccination (n = 1106/1442)c 0.83 (0.54–1.3) 1.1 (0.59–1.9) 1.1 (0.65–1.8) 1.6 (0.78–3.2)
Chronic respiratory disease (n = 148/1613) 1.2 (0.69–2.1) 0.79 (0.35–1.8) 1.3 (0.68–2.3) 0.74 (0.29–1.9)
Had an upper respiratory infection during Hajjd (n = 412/1409) 1.5 (0.98–2.2) 1.2 (0.69–2.0) 1.6 (0.99–2.5) 1.5 (0.83–2.7)
Shared room with at least one person with upper respiratory
infectiond (n = 750/1613)
1.1 (0.80–1.6) 1.2 (0.69–2.2) 1.1 (0.72–1.6) 1.1 (0.57–2.2)
Used antibiotics during Hajjd (n=379/1424) 0.83 (0.52–1.3) 0.96 (0.52–1.8) 1.0 (0.62–1.7) 1.1 (0.55–2.1)
Abbreviations: OR, odds ratio; PR, prevalence ratio.
aNumber with characteristics/total number with information available.
bFor multivariate analyses all variables were included simultaneously; additionally year and days at the Hajj when a swab was collected were included. For the beginning-Hajj cohort
Nagelkerke’s pseudo R-square values were 0.061 for the model with any carriage and 0.052 for the model with non-susceptible pneumococcal carriage as the outcome; for the end-
Hajj cohort these values were 0.019 and 0.021.
cIn the beginning-Hajj cohort, 122 of 126 persons with pneumococcal vaccination also reported inﬂuenza vaccination as did 134 of 136 persons in the end-Hajj cohort; consequently,
these vaccinations were grouped together.
dThese variables are relevant only for the end-Hajj participants because they occurred during the Hajj.
CMI Memish et al. Hajj pneumococcal carriage ampliﬁcation 77.e15As noted above, serotype 3 was the most prevalent serotype
overall. During 2011, ﬁve beginning-Hajj and 12 end-Hajj
serotype 3 isolates were found while during 2012, two pre-
Hajj and 14 post-Hajj isolates were found. Among thisFIG. 1. Pneumococcal serotype distribution by year and beginning-Hajj vers
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Incommon serotype a wide variety of STs were identiﬁed with no
evidence of expansion over a single year or between years; for
example, the most common ST was 700 with 13 instances but
nine of these occurred among the 2012 Africa end-Hajj cohortus end-Hajj cohorts.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e11–77.e18
77.e16 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMI(see Supporting information, Table S3). A similar phenomenon
was observed for other common serotypes. We observed a
serotype 19F and a serotype 23F with the same ST 9213.DiscussionPneumonia is a leading cause of hospitalization of pilgrims
during the Hajj, one of the biggest and most geographically
diverse mass gatherings in the world [6,9,10]. Streptococcus
pneumoniae is a common pathogen isolated from patients with
pneumonia and respiratory tract infections during the Hajj
[10,12,13]. Due to the population ﬂow and dynamics during
Hajj, this event has the potential to increase pneumococcal
carriage among pilgrims.
Our results support the hypothesis that the Hajj increases
prevalence of pneumococcal colonization as measured by lower
pneumococcal carriage prevalence at the beginning compared
with the end of the Hajj. A recent small-scale carriage study that
enrolled fewer than 200 subjects found a similar effect [11].
Several mechanisms could account for this increase in carriage at
the end of the Hajj. A single invasive clone could have expanded
during the Hajj. The crowded conditions at the Hajj may amplify
pneumococcal transmission. Similarly, transmission among pil-
grims may increase through interaction with local residents.
Finally, widespread antibiotic use during the Hajj [17,18] may
select for resistant clones that aremore likely to persist in carriage.
Our results help to address the likelihood of some of these
possibilities. The lack of increased carriage from more invasive
isolates, propagation of any particular ST, and relationship be-
tween STs at the beginning and end of the Hajj would seem to
rule out a Hajj effect in spreading a single virulent clone. The
increase in overall carriage, rather than simply an increase in
the proportion of resistant organisms, suggests that trans-
mission increased during the Hajj. If transmission increased, the
lack of association between duration of time at the Hajj and
carriage suggests that a new steady state of transmission is
achieved relatively quickly after arrival. Pilgrims from some
countries (such as Indonesia) had large increases in carriage
while others (such as India) had no change at all; carriage
increased substantially during 2012 but little during 2011; and
carriage did not increase for those aged <50 years. These data
indicate that any impact of the Hajj on transmission is inﬂu-
enced by other factors. Finally, carriage of antibiotic non-
susceptible organisms increased but was not associated with
self-reported antibiotic use; this suggests that the Hajj does not
promote development of newly resistant strains, but rather
selects for resistant organisms.
The MLST data conﬁrm the pluriformity of carried
S. pneumoniae, with a different set of clones in each cohortClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectdeﬁned by a combination of study year, continent of residence
and beginning versus end Hajj. Within cohorts, some clones
were relatively more common (e.g. ST 700, ST 9220) but no
single clone was identiﬁed that seemed to expand during the
course of Hajj. Our observation that serotype 3 was the only
serotype that appeared across most groups, and expanded in
several end of Hajj groups despite no obvious expansion in STs,
suggests that expansion was associated with serotype and not
ST. Nevertheless, ﬁrm conclusions are difﬁcult. We conducted
four cross-sectional studies and though our study was relatively
large, it included much less than 1% of pilgrims; consequently,
we may have missed a modest clonal expansion. To further
deﬁne this issue, it will be necessary to conduct a true cohort
study following the same pilgrims from the beginning to the end
of the Hajj.
Taken as a whole, these data suggest that the Hajj increases
overall pneumococcal transmission, with selection for partic-
ular strains, especially those with antibiotic resistance. In sup-
port of this interpretation, two out of the three most common
serotypes (3 and 19F) had higher carriage prevalence at the end
than the beginning of the Hajj and were characterized by a high
proportion of antibiotic non-susceptibility. By contrast, the
third most common serotype (34), which had a relatively low
proportion of antibiotic non-susceptible isolates, had lower
carriage prevalence among the end-Hajj cohort. Additionally, at
least during 2012, there was evidence that the number of MLST
patterns as a proportion of all isolates decreased during the
course of the Hajj, again suggesting a selection process.
Serotypes with higher invasive indices can cause endemic
disease, for example in the African meningitis belt [28–30], as
well as localized outbreaks [31–33]. We identiﬁed only nine
total pneumococci with serotypes associated with a higher
invasiveness index (three at the beginning of the Hajj and six at
the end). Low carriage prevalence of invasive serotypes is not
surprising given that invasiveness is deﬁned as a low ratio of
carriage to invasive disease. Additionally, the low carriage
prevalence at the beginning of the Hajj made it difﬁcult to assess
a Hajj effect. Nevertheless, the lack of a large increase does
suggest lack of preferential selection for these more invasive
serotypes.
We found a low overall carriage prevalence for unknown
reasons. We conducted only nasopharyngeal testing while some
studies have shown that the addition of oropharyngeal samples
increases yield, particularly in adults [25,28]. High antibiotic use
among pilgrims before or shortly after Hajj arrival may have
masked or eliminated carriage of susceptible isolates in the
beginning-Hajj sample, although we know of no data to support
this hypothesis; similarly, antibiotic use during the Hajj could
have reduced detection among the end-Hajj cohort, although
this seems unlikely as reported antibiotic use did not predictious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e11–77.e18
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carriage and detection of carriage makes it problematic to know
whether the Hajj promotes a true selection for non-susceptible
isolates or whether this represents diagnostic bias.
Our results are limited primarily by the cross-sectional
rather than longitudinal study design. Consequently, our re-
sults could be confounded by unmeasured factors. In this
respect, it is encouraging that we identiﬁed a Hajj effect for
most analysed sub-groups, albeit to a lesser extent in 2011. Our
study had several other limitations. We included only two
measurement points, making it difﬁcult to describe more
thoroughly carriage dynamics during the Hajj period. Although
our cohorts were large they represented a small fraction of the
total pilgrims attending the Hajj, so our results cannot be
extrapolated to all pilgrims. Notwithstanding these limitations,
we have sampled a large number of pilgrims in a period span-
ning two Hajj seasons and reported that this event increases
S. pneumoniae nasopharyngeal carriage and selects for speciﬁc
serotypes and antibiotic non-susceptible strains. Last, we report
an association between previous inﬂuenza or PPV23 immuni-
zation and carriage as well as effect modiﬁcation between im-
munization history and increase in carriage during the Hajj;
however, the self-reported nature of immunization history
makes it impossible to interpret these data, including whether
this represents a true effect or confounding because vaccinated
persons have different carriage risks than unvaccinated persons.
Our study results do not lead to obvious public health
recommendations for pneumococcal vaccination of pilgrims.
On one hand, we found that Hajj increases S. pneumoniae
nasopharyngeal carriage and selects for speciﬁc serotypes and
antibiotic non-susceptible strains; we also found that older
persons (a sizable proportion of Hajjis) have increased carriage
prevalence. On the other hand, while effective 13-valent and
10-valent PCVs exist, they would cover only 37% and 18% of
identiﬁed pneumococci respectively; moreover, the distribution
of carried strains does not accurately predict strains causing
disease [34]. Also, currently there is a lack of evidence that
pilgrims experience a particularly high pneumococcal disease
incidence, and any increase in carriage among pilgrims could be
short-lived once they return home. Further studies will help to
address these issues. These may include additional carriage
studies with a longitudinal design and ideally multiple testing
points, as well as studies to determine the burden of pneu-
mococcal disease syndromes during and after the Hajj.Appendix A. Supplementary dataSupplementary data related to this article can be found at http://
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